Free tool
Stocks listed on Nasdaq GM
We cover 58 companies listed on Nasdaq GM. The median market value in the group is $3.56B. Across the group, the median move over the past trading day is −0.54%. 65% of the 57 with a 200-day average trade above it. Price change over the past year runs from −43.4% to +266.4% across the middle 80 percent of the group, with a median of +31.1%.
Other lists in this group
Table
58 of 701 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return |
|---|---|---|---|---|
| PTGX | Protagonist Therapeutics, Inc. | $9.80B | Mid cap | +146.62% |
| NUVL | Nuvalent Inc | $9.79B | Mid cap | +62.83% |
| AAOI | Applied Optoelectronics, Inc. Common Stock | $9.66B | Mid cap | +373.01% |
| APPF | AppFolio, Inc. | $7.90B | Mid cap | −19.22% |
| RYTM | Rhythm Pharmaceuticals, Inc. | $7.78B | Mid cap | +9.35% |
| CAMT | Camtek Ltd. | $6.69B | Mid cap | +64.84% |
| MAAS | Maase Inc. | $6.63B | Mid cap | +265.19% |
| LNTH | Lantheus Holdings, Inc. | $6.58B | Mid cap | +77.38% |
| ORKA | Oruka Therapeutics, Inc. | $6.58B | Mid cap | +555.07% |
| GDS | GDS Holdings Limited | $6.52B | Mid cap | −3.30% |
| TVTX | Travere Therapeutics, Inc. | $6.24B | Mid cap | +284.86% |
| XENE | Xenon Pharmaceuticals Inc. | $6.18B | Mid cap | +64.11% |
| TTD | The Trade Desk, Inc. | $6.12B | Mid cap | −75.25% |
| RDNT | RadNet, Inc. | $6.05B | Mid cap | +7.27% |
| MIRM | Mirum Pharmaceuticals, Inc. | $5.98B | Mid cap | +31.96% |
| LGND | Ligand Pharmaceuticals Incorporated | $5.74B | Mid cap | +80.92% |
| CRSP | CRISPR Therapeutics AG | $5.73B | Mid cap | +10.65% |
| ACMR | ACM Research, Inc. | $5.51B | Mid cap | +176.80% |
| ENPH | Enphase Energy, Inc. | $4.92B | Mid cap | +2.28% |
| DAVE | Dave Inc. | $4.75B | Mid cap | +79.15% |
| RUM | RUM Group Inc. | $4.65B | Mid cap | +24.17% |
| USAR | USA Rare Earth, Inc. | $4.63B | Mid cap | +20.59% |
| OLLI | Ollie's Bargain Outlet Holdings, Inc. | $4.49B | Mid cap | −43.13% |
| TNGX | Tango Therapeutics, Inc. | $4.29B | Mid cap | +269.13% |
| RLAY | Relay Therapeutics, Inc. | $4.26B | Mid cap | +445.10% |
| FLY | Firefly Aerospace Inc. | $3.73B | Mid cap | −52.67% |
| IOVA | Iovance Biotherapeutics, Inc. | $3.66B | Mid cap | +233.88% |
| FRPT | Freshpet, Inc. | $3.62B | Mid cap | +30.33% |
| VCYT | Veracyte, Inc. Common Stock | $3.56B | Mid cap | +54.81% |
| GPCR | Structure Therapeutics Inc. | $3.56B | Mid cap | +159.74% |
| NMIH | NMI Holdings Inc. Class A Common Stock | $3.40B | Mid cap | +13.73% |
| CSQ | Calamos Strategic Total Return Fund | $3.34B | Mid cap | +18.32% |
| NVTS | Navitas Semiconductor Corporation | $3.31B | Mid cap | +108.73% |
| NAMS | NewAmsterdam Pharma Company N.V. | $3.27B | Mid cap | +11.97% |
| TMDX | TransMedics Group, Inc. | $3.19B | Mid cap | −21.43% |
| IRON | Disc Medicine, Inc. | $3.17B | Mid cap | +37.90% |
| SOUN | SoundHound AI, Inc. | $3.11B | Mid cap | −41.14% |
| NRIX | Nurix Therapeutics, Inc. | $2.77B | Mid cap | +179.69% |
| APPN | Appian Corporation | $2.75B | Mid cap | +30.34% |
| LUNR | Intuitive Machines, Inc. | $2.66B | Mid cap | +79.20% |
| VERA | Vera Therapeutics, Inc. | $2.65B | Mid cap | +67.21% |
| DJT | Trump Media & Technology Group Corp. | $2.64B | Mid cap | −46.99% |
| SUPN | Supernus Pharmaceuticals, Inc. | $2.61B | Mid cap | −0.42% |
| TRVI | Trevi Therapeutics, Inc. | $2.55B | Mid cap | +124.00% |
| KOD | Kodiak Sciences Inc. | $2.48B | Mid cap | +321.09% |
| EMAT | Evolution Metals & Technologies Corp. | $2.45B | Mid cap | −82.32% |
| PAYO | Payoneer Global Inc. | $2.41B | Mid cap | +4.86% |
| FIVN | Five9, Inc. | $2.39B | Mid cap | +18.47% |
| OCUL | Ocular Therapeutix, Inc. | $2.37B | Mid cap | −12.58% |
| HRMY | Harmony Biosciences Holdings, Inc. | $2.31B | Mid cap | +4.23% |
| URGN | UroGen Pharma Ltd. | $2.25B | Mid cap | +135.11% |
| PVLA | Palvella Therapeutics, Inc. | $2.22B | Mid cap | +173.39% |
| AUPH | Aurinia Pharmaceuticals Inc. | $2.20B | Mid cap | +36.58% |
| VERX | Vertex, Inc. | $2.19B | Mid cap | −46.34% |
| PLBL | Polibeli Group Ltd | $2.18B | Mid cap | −35.97% |
| VCEL | Vericel Corporation | $2.17B | Mid cap | +18.25% |
| ADMA | ADMA Biologics, Inc. | $2.16B | Mid cap | −44.17% |
| KEEL | Keel Infrastructure Corp. | $2.08B | Mid cap | +150.75% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.